HomeCompareLBYAV vs PFE

LBYAV vs PFE: Dividend Comparison 2026

LBYAV yields 18.37% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBYAV wins by $16.5K in total portfolio value
10 years
LBYAV
LBYAV
● Live price
18.37%
Share price
$10.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$66.0K
Annual income
$5,637.49
Full LBYAV calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LBYAV vs PFE

📍 LBYAV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBYAVPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBYAV + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBYAV pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBYAV
Annual income on $10K today (after 15% tax)
$1,561.07/yr
After 10yr DRIP, annual income (after tax)
$4,791.87/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $17,528.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBYAV + PFE for your $10,000?

LBYAV: 50%PFE: 50%
100% PFE50/50100% LBYAV
Portfolio after 10yr
$57.8K
Annual income
$15,948.11/yr
Blended yield
27.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LBYAV
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBYAV buys
2
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$LBYAV▼ Sell$1,001 - $15,0002024-11-13
Thomas H. Kean🏢 House$LBYAV▼ Sell$15,001 - $50,0002024-11-13
Ro Khanna🏢 House$LBYAV▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$LBYAV▼ Sell$1,001 - $15,0002023-11-03
Ro Khanna🏢 House$LBYAV▼ Sell$15,001 - $50,0002023-10-10
Daniel Goldman🏢 House$LBYAV▼ Sell$1,001 - $15,0002023-07-12
Ro Khanna🏢 House$LBYAV▲ Buy$1,001 - $15,0002022-09-29
Ro Khanna🏢 House$LBYAV▲ Buy$15,001 - $50,0002022-09-29
Ro Khanna🏢 House$LBYAV▼ Sell$1,001 - $15,0002022-01-21
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBYAVPFE
Forward yield18.37%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$66.0K$49.6K
Annual income after 10y$5,637.49$26,258.71
Total dividends collected$35.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LBYAV vs PFE ($10,000, DRIP)

YearLBYAV PortfolioLBYAV Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,537$1,836.55$9,153$693.39+$3.4KLBYAV
2$15,566$2,151.77$8,593$849.25+$7.0KLBYAV
3$19,152$2,496.94$8,336$1,066.78+$10.8KLBYAV
4$23,364$2,871.27$8,437$1,384.80+$14.9KLBYAV
5$28,273$3,273.57$9,013$1,875.40+$19.3KLBYAV
6$33,955$3,702.22$10,306$2,680.72+$23.6KLBYAV
7$40,487$4,155.28$12,820$4,101.38+$27.7KLBYAV
8$47,952$4,630.53$17,673$6,826.70+$30.3KLBYAV
9$56,434$5,125.48$27,543$12,591.86+$28.9KLBYAV
10$66,021$5,637.49$49,560$26,258.71+$16.5KLBYAV

LBYAV vs PFE: Complete Analysis 2026

LBYAVStock

Liberty Global Ltd., together with its subsidiaries, provides broadband internet, video, fixed-line telephony, and mobile communications services to residential and business customers. It offers value-added broadband services, such as WiFi features, security, anti-virus, firewall, spam protection, smart home services, online storage solutions, and web spaces; and Connect Box that delivers in-home Wi-Fi service. The company provides various tiers of digital video programming and audio services, as well as digital video recorders and multimedia home gateway systems; Horizon 5, a cloud-based, multi-screen entertainment platform that combines linear television, including recording and replay features and video-on-demand services; Horizon Go, an online mobile app; and channels, including general entertainment, sports, movies, series, documentaries, lifestyles, news, adult, children, and ethnic and foreign channels. In addition, it offers postpaid and prepaid mobile services; circuit-switched telephony services; and personal call manager, unified messaging, and a second or third phone line at an incremental cost. Further, the company offers business services comprising voice, advanced data, video, wireless, cloud-based services, and mobile and converged fixed-mobile services to small or home offices, small businesses, and medium and large enterprises, as well as on a wholesale basis to other operators. It operates in Belgium, Switzerland, Ireland, Slovakia, and internationally. Liberty Global Ltd. was founded in 2004 and is based in Hamilton, Bermuda.

Full LBYAV Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LBYAV vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBYAV vs SCHDLBYAV vs JEPILBYAV vs OLBYAV vs KOLBYAV vs MAINLBYAV vs JNJLBYAV vs MRKLBYAV vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.